Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder

References

• Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet. 2016 Apr;387(10027):1561–72.
   PubMed Web of Science ®Google Scholar
• Pedersen CB, Mors O, Bertelsen A, et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA psychiatry. 2014 May 1;71(5):573–581.
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011 Mar 7;68(3):241–251.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
   Google Scholar
• Machado-Vieira R, Luckenbaugh DA, Ballard ED, et al. Increased activity or energy as a primary criterion for the diagnosis of bipolar mania in DSM-5: findings from the STEP-BD study. Am J Psychiatry. 2017 Jan 1;174(1):70–76.
   PubMed Web of Science ®Google Scholar
• Leboyer M, Kupfer DJ. Bipolar disorder. J Clin Psychiatry. 2010 Dec 15;71(12):1689–1695.
   PubMed Web of Science ®Google Scholar
• Bowie CR, Depp C, McGrath JA, et al. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am J Psychiatry. 2010 Sep;167(9):1116–1124.
   PubMed Web of Science ®Google Scholar
• Ferrari AJ, Stockings E, Khoo J-P, et al. The prevalence and burden of bipolar disorder: findings from the global burden of disease study 2013. Bipolar Disord. 2016 Aug;18(5):440–450.
   PubMed Web of Science ®Google Scholar
• Swann AC. Long-term treatment in bipolar disorder. J Clin Psychiatry. 2005;66(Suppl 1):7–12.
   PubMedGoogle Scholar
• Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013 May 11;381(9878):1672–1682.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006 Feb;163(2):217–224.
   PubMed Web of Science ®Google Scholar
• Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002 Mar;105(3):164–172.
   PubMed Web of Science ®Google Scholar
• Keck PE, McElroy SL, Strakowski SM, et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry. 1996 Jul;57(7):292–297.
   PubMed Web of Science ®Google Scholar
• Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;63(5):384–90.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 2006;8:618–624.
   PubMed Web of Science ®Google Scholar
• Keck PE, McElroy SL, Strakowski SM, et al. 12-Month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry. 1998 May;155(5):646–652.
   PubMed Web of Science ®Google Scholar
• Strakowski SM, Keck PE, McElroy SL, et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry. 1998 Jan;55(1):49–55.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S. Treatment-adherence in bipolar disorder: A patient-centred approach. World J Psychiatry. 2016 Dec 22;6(4):399–409.
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E, Tacchi MJ, et al. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord. 2005 Dec 7;Suppl 5 (s5):24–31.
   PubMedGoogle Scholar
• Thase ME. Strategies for increasing treatment adherence in bipolar disorder. J Clin Psychiatry. 2012 Feb 15;73(02):e08.
   PubMedGoogle Scholar
• Drugs@FDA. FDA Approved Drug Products; U.S. Food and Drug Administration. Silver Spring, MD: U.S. Food and Drug Administration; 2017.
   Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97–17.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British association for psychopharmacology. J Psychopharmacol. 2016 Jun 15;30(6):495–553.
   PubMed Web of Science ®Google Scholar
• Kendall T, Morriss R, Mayo-Wilson E, et al. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ. 2014 Sep 25;349(sep25 5):g5673–g5673.
   PubMedGoogle Scholar
• Yildiz A, Nikodem M, Vieta E, et al. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. 2015 Jan 18;45(2):299–317.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011 Oct 8;378(9799):1306–1315.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Hirschfeld RMA, Frye MA, et al. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry. 2004 Nov;65(11):1499–1504.
   PubMed Web of Science ®Google Scholar
• Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010 Feb 15;71(2):150–162.
   PubMed Web of Science ®Google Scholar
• Morsel AM, Morrens M, Sabbe B. An overview of pharmacotherapy for bipolar I disorder. Expert Opin Pharmacother. 2018 Feb 11;19(3):203–222.
   PubMed Web of Science ®Google Scholar
• Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004 Feb;161(2):217–222.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. divalproex maintenance study group. Arch Gen Psychiatry. 2000 May;57(5):481–489.
   PubMed Web of Science ®Google Scholar
• Berk M, Daglas R, Dandash O, et al. Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial. Br J Psychiatry. 2017 Jun 2;210(6):413–421.
   PubMed Web of Science ®Google Scholar
• Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder. J Affect Disord. 2008 Aug;109(3):251–263.
   PubMed Web of Science ®Google Scholar
• Keck PE, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007 Oct;68(10):1480–1491.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010 Jul 15;68(2):156–162.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003 Sep;64(9):1013–1024.
   PubMed Web of Science ®Google Scholar
• ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension, for intramuscular use [package insert]. Tokyo (Japan): Otsuka Pharmaceuticals Co. Ltd.; 2015. [Cited 2018 Aug 13]. Available from: https://www.otsuka-us.com/media/static/Abilify-M-PI.pdf
   Google Scholar
• Potkin SG, Preda A. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert Opin Pharmacother. 2016;17(3):395–407.
   PubMed Web of Science ®Google Scholar
• Tuplin EW, Holahan MR. Aripiprazole, a drug that displays partial agonism and functional selectivity. Curr Neuropharmacol. 2017 Nov 14;15(8):1192–1207.
   PubMed Web of Science ®Google Scholar
• Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16(5):488–501.
   PubMed Web of Science ®Google Scholar
• De Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015 Sep 7;29(9):773–799.
   PubMed Web of Science ®Google Scholar
• Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004;10(4):317–336.
   PubMedGoogle Scholar
• McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66(Suppl 3):28–36.
   PubMed Web of Science ®Google Scholar
• Agency EM. Abilify Maintena (Aripiprazole); 2015. [cited 2018 Aug 13]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002755/human_med_001711.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004 Feb;44(2):179–187.
   PubMed Web of Science ®Google Scholar
• Raoufinia A, Peters-Strickland T, Nylander A-G, et al. Aripiprazole once-monthly 400 mg: comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration. Int J Neuropsychopharmacol. 2017 Apr 1;20(4):295–304.
   PubMed Web of Science ®Google Scholar
• Casey AB, Canal CE. Classics in chemical neuroscience: aripiprazole. ACS Chem Neurosci. 2017;8(6):1135–1146.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Shoaf SE, Boulton DW, et al. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet. 2008;47(8):533–542.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281–288.
   PubMed Web of Science ®Google Scholar
• Van Der Weide K., van der Weide J. The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol. 2015 Jun;35(3):228–236.
   PubMed Web of Science ®Google Scholar
• Hendset M, Molden E, Knape M, et al. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. Ther Drug Monit. 2013 Nov;36(1):1.
   Web of Science ®Google Scholar
• Lisbeth P, Vincent H, Kristof M, et al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175–184.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder. J Clin Psychiatry. 2017 Mar 29;78(3):324–331.
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012 May 15;73(5):617–624.
   PubMed Web of Science ®Google Scholar
• Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005 Jan;45(1):89–93.
   PubMed Web of Science ®Google Scholar
• Boulton DW, Kollia GD, Mallikaarjun S, et al. Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole. J Clin Pharm Ther. 2012 Oct;37(5):565–570.
   PubMed Web of Science ®Google Scholar
• Keck PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute Bipolar mania. Am J Psychiatry. 2003 Sep;160(9):1651–1658.
   PubMed Web of Science ®Google Scholar
• Keck PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006 Apr;67(4):626–637.
   PubMed Web of Science ®Google Scholar
• Mansell W, Colom F, Scott J. The nature and treatment of depression in bipolar disorder: a review and implications for future psychological investigation. Clin Psychol Rev. 2005 Dec;25(8):1076–1100.
   PubMed Web of Science ®Google Scholar
• Bellivier F. Cognitions and functioning in euthymic bipolar patients: screening and treatment. Encephale. 2012 Dec;38(Suppl 4):S151–S154.
   PubMedGoogle Scholar
• Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand Suppl. 2007 Oct;116(434):50–56.
   Google Scholar
• Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009 Dec;11(8):827–839.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.janssenprescriptionassistance.com/risperdal-consta-cost-assistance.[Last accessed 2018 Aug 13]
   Google Scholar